Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Donald F. LeGatt"'
Publikováno v:
Clinical chemistry. 63(7)
An 85-year-old man presented to the emergency department with delirium. He was taking the anticonvulsant primidone to manage essential tremors. His estimated glomerular filtration rate was low at 52 mL/min/1.72 m2. A urine barbiturate drug screen was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc34b250c8023e882e44c3623c246b78
https://pubmed.ncbi.nlm.nih.gov/28659400
https://pubmed.ncbi.nlm.nih.gov/28659400
Autor:
Cheryl A. Vesso, Jean S. Der, Roberta A. Martindale, Donald F. LeGatt, Jennifer L. Crawford, George S. Cembrowski, Lucille J. Journault, Carol Shalapay, Chi Tran, Cathy W. Revers, Connie Prosser, Tammy L. Hofer, Bev J. Rintoul
Publikováno v:
Laboratory Medicine. 37:347-351
One of the most frequent quality control issues faced by laboratory professionals is how to respond appropriately to a shift in quality control (QC) following a reagent lot change. Possible actions include adjusting the control range, checking for sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eda1e4e8538165769cf5c4a51bcd61d
https://doi.org/10.1309/brc6y37nm3bu97wx
https://doi.org/10.1309/brc6y37nm3bu97wx
Publikováno v:
Clinical Biochemistry. 30:155-162
Objective: The purpose of this work was to develop applications for the EMIT® Cyclosporine (CsA) Assay on the Hitachi 911 and 917 analyzers. Methods and Results: Instrument settings were optimized to arrive at the following assay characteristics on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d7a589e9e56c9e68bd21021aa738e2
https://doi.org/10.1016/s0009-9120(96)00162-2
https://doi.org/10.1016/s0009-9120(96)00162-2
Publikováno v:
Clinical Chemistry. 43:104-108
The new oral formulation of cyclosporine (CsA), Neoral® (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be5bc97088f6d960672591b2ab03458d
https://doi.org/10.1093/clinchem/43.1.104
https://doi.org/10.1093/clinchem/43.1.104
Autor:
Suren N. Sehgal, Steven J. Soldin, Roger L. Boeckx, David W. Holt, Barry D. Kahan, Randall W. Yatscoff, Kimberly L. Napoli, Calvin R. Stiller, Donald F. LeGatt
Publikováno v:
Therapeutic Drug Monitoring. 17:676-680
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8898045316b3d1a67d4c0dfdf3bb52ee
https://doi.org/10.1097/00007691-199512000-00022
https://doi.org/10.1097/00007691-199512000-00022
Publikováno v:
Therapeutic Drug Monitoring. 17:454-459
Leflunomide (HWA 486, LEF) is a novel isoxazole derivative with potent immunosuppressive properties. LEF is converted to its active metabolite (A77 1726) after absorption. Presently, the blood distribution and pharmacokinetics of LEF have not been re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a632eb6f7899db473172c6e631c6f711
https://doi.org/10.1097/00007691-199510000-00004
https://doi.org/10.1097/00007691-199510000-00004
Publikováno v:
Clinical Chemistry. 41:295-299
Pharmacodynamic monitoring of the biological effect of immunosuppressive drugs provides an alternative to traditional therapeutic drug monitoring. We chose this method to investigate mycophenolic acid (MPA), an immunosuppressive drug that mediates it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54f02309d840ac62408b17946cf129c6
https://doi.org/10.1093/clinchem/41.2.295
https://doi.org/10.1093/clinchem/41.2.295
Publikováno v:
Therapeutic Drug Monitoring. 17:84-88
The immunosuppressive activity of leflunomide is expressed after conversion to its pharmacologically active metabolite A77 1726. Leflunomide is a potent immunosuppressant that inhibits both T-cell and B-cell activity. To date, no pharmacokinetic data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f17baea431adb7ece7ff9c47af3bf582
https://doi.org/10.1097/00007691-199502000-00014
https://doi.org/10.1097/00007691-199502000-00014
Autor:
Eduardo Bruera, Donald F. Legatt, Najib Babul, Andrew C. Darke, Tara MacEachern, Zoltan Harsanyi, Kathy. Spachynski, R. Neil MacDonald
Publikováno v:
Cancer. 74:3204-3211
Background The short elimination half-life of metoclopramide necessitates frequent administration for optimal relief of nausea. This study compares a newly developed controlled release preparation of metoclopramide (CRM) and immediate release metoclo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a8356cedfa04896abc556cc2d9fb43d
https://doi.org/10.1002/1097-0142(19941215)74:12<3204::aid-cncr2820741220>3.0.co
https://doi.org/10.1002/1097-0142(19941215)74:12<3204::aid-cncr2820741220>3.0.co
Publikováno v:
Therapeutic Drug Monitoring. 15:478-482
Rapamycin (RAPA) is a new immunosuppressive drug with a potency similar to that of FK506 and up to a 100-fold greater than that of cyclosporine (CsA). RAPA has shown to be efficacious in the prolongation of allograft survival in a number of animal mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b52f19e359617c55b9e8e7b718a61df
https://doi.org/10.1097/00007691-199312000-00004
https://doi.org/10.1097/00007691-199312000-00004